Top

Published in:

01-05-2021 | Acute Myeloid Leukemia | Review Article

The role of various interleukins in acute myeloid leukemia

Authors: Erin C. Kaser, Lei Zhao, Kyle P. D’mello, Ziwen Zhu, Huaping Xiao, Mark R. Wakefield, Qian Bai, Yujiang Fang

Published in: Medical Oncology | Issue 5/2021

Abstract

Interleukins are signaling molecules involved in the immune system, and they play a variety of roles in different diseases and cancers. Acute myeloid leukemia (AML) is the most common type of leukemia in adults, and survival rate after diagnosis is very low. Investigating the role interleukins play in AML can help understand the progression of the disease. There exists a need for more effective treatment of AML. Interleukins can be used to guide immunotherapy for AML. This review article will examine how specific interleukins play a role in AML disease progression and how they can be utilized as a future treatment option.

Elmslie RE, Dow SW, Ogilvie GK. Interleukins: biological properties and therapeutic potential. J Vet Intern Med. 1991;5(5):283–93. https://doi.org/10.1111/j.1939-1676.1991.tb03135.x.CrossRefPubMed

Davis MR, Zhu Z, Hansen DM, Bai Q, Fang Y. The role of IL-21 in immunity and cancer. Cancer Lett. 2015;358(2):107–14. https://doi.org/10.1016/j.canlet.2014.12.047.CrossRefPubMed

Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015;367(2):103–7. https://doi.org/10.1016/j.canlet.2015.07.009.CrossRefPubMed

Dmitrieva O, Shilovskiy I, Khaitov M, Grivennikov S. Interleukins 1 and 6 as main mediators of inflammation and cancer. Biochem Mosc. 2016;81(2):80–90.CrossRef

Setrerrahmane S, Xu H. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017;16(1):153. https://doi.org/10.1186/s12943-017-0721-9.CrossRefPubMedPubMedCentral

Davis AS, Viera AJ, Mead MD. Leukemia: an overview for primary care. Am Fam Physician. 2014;89(9):731–8.PubMed

Ratnam KV, Khor CJ, Su WP. Leukemia cutis. Dermatol Clin. 1994;12(2):419–31.CrossRef

Imai K. Acute lymphoblastic leukemia: pathophysiology and current therapy. Rinsho Ketsueki. 2017;58(5):460–70. https://doi.org/10.11406/rinketsu.58.460.CrossRefPubMed

Stanulla M, Cave H, Moorman AV. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? Blood. 2020;135(4):252–60. https://doi.org/10.1182/blood.2019000813.CrossRefPubMedPubMedCentral

10.

De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441. https://doi.org/10.1038/bcj.2016.50.CrossRefPubMedPubMedCentral

11.

Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099–107. https://doi.org/10.1002/cncr.22233.CrossRefPubMed

12.

Prada-Arismendy J, Arroyave JC, Rothlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31(1):63–76. https://doi.org/10.1016/j.blre.2016.08.005.CrossRefPubMed

13.

Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52.CrossRef

14.

Martner A, Thoren FB, Aurelius J, Soderholm J, Brune M, Hellstrand K. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia. Expert Rev Hematol. 2010;3(4):381–91. https://doi.org/10.1586/ehm.10.30.CrossRefPubMed

15.

Fei C, Yao XM, Sun Y, Gu XZ, Yu LQ, Lai X. Interleukin-10 polymorphisms associated with susceptibility to acute myeloid leukemia. Genet Mol Res. 2015;14(1):925–30. https://doi.org/10.4238/2015.February.2.15.CrossRefPubMed

16.

Tao Q, Pan Y, Wang Y, Wang H, Xiong S, Li Q, et al. Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts. Int J Cancer. 2015;137(10):2384–93. https://doi.org/10.1002/ijc.29563.CrossRefPubMed

17.

Nakase K, Kita K, Katayama N. IL-2/IL-3 interplay mediates growth of CD25 positive acute myeloid leukemia cells. Med Hypotheses. 2018;115:5–7. https://doi.org/10.1016/j.mehy.2018.03.007.CrossRefPubMed

18.

Cozzolino F, Rubartelli A, Aldinucci D, Sitia R, Torcia M, Shaw A, et al. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci. 1989;86(7):2369–73.CrossRef

19.

Vijay V, Miller R, Vue GS, Pezeshkian MB, Maywood M, Ast AM, et al. Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. Leuk Res. 2019;84:106180. https://doi.org/10.1016/j.leukres.2019.106180.CrossRefPubMedPubMedCentral

20.

Nishioka C, Ikezoe T, Pan B, Xu K, Yokoyama A. Micro RNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells. Cancer Sci. 2017;108(4):685–95.CrossRef

21.

Ferretti E, Di Carlo E, Cocco C, Ribatti D, Sorrentino C, Ognio E, et al. Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett. 2010;133(2):99–105. https://doi.org/10.1016/j.imlet.2010.08.002.CrossRefPubMed

22.

Wróbel T, Gębura K, Wysoczańska B, Jaźwiec B, Dobrzyńska O, Mazur G, et al. IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia. J Cancer Res Clin Oncol. 2014;140(9):1551–5.CrossRef

23.

Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S. Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci. 2014;105(8):933–42. https://doi.org/10.1111/cas.12459.CrossRefPubMedPubMedCentral

24.

Wang J, Tao Q, Wang H, Wang Z, Wu F, Pan Y, et al. Elevated IL-35 in bone marrow of the patients with acute myeloid leukemia. Hum Immunol. 2015;76(9):681–6. https://doi.org/10.1016/j.humimm.2015.09.020.CrossRefPubMed

25.

Huang J, Liu Y, Au BC, Barber DL, Arruda A, Schambach A, et al. Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Mol Ther Methods Clin Dev. 2016;3:16074. https://doi.org/10.1038/mtm.2016.74.CrossRefPubMedPubMedCentral

26.

Gutierrez A, Kentsis A. Acute myeloid/T-lymphoblastic leukaemia (AMTL): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy. Br J Haematol. 2018;180(6):919–24. https://doi.org/10.1111/bjh.15129.CrossRefPubMedPubMedCentral

27.

Xu DH, Zhu Z, Xiao H, Wakefield MR, Bai Q, Nicholl MB, et al. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma. Cancer Lett. 2017;394:43–51.CrossRef

28.

Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):377–90. https://doi.org/10.1016/j.cytogfr.2014.07.018.CrossRefPubMed

29.

Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, et al. IL-2 and beyond in cancer immunotherapy. J Interferon Cytokine Res. 2018;38(2):45–68. https://doi.org/10.1089/jir.2017.0101.CrossRefPubMedPubMedCentral

30.

Berraondo P, Etxeberria I, Ponz-Sarvise M, Melero I. Revisiting interleukin-12 as a cancer immunotherapy agent. Clin Cancer Res. 2018;24(12):2716–8.CrossRef

31.

Anestakis D, Petanidis S, Kalyvas S, Nday CM, Tsave O, Kioseoglou E, et al. Mechanisms and αpplications of ιnterleukins in cancer immunotherapy. Int J Mol Sci. 2015;16(1):1691–710.CrossRef

32.

Kampan NC, Xiang SD, McNally OM, Stephens AN, Quinn MA, Plebanski M. Immunotherapeutic interleukin-6 or interleukin-6 receptor blockade in cancer: challenges and opportunities. Curr Med Chem. 2018;25(36):4785–806. https://doi.org/10.2174/0929867324666170712160621.CrossRefPubMed

33.

Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8(357):357123. https://doi.org/10.1126/scitranslmed.aaf2341.CrossRef

34.

Van Acker HH, Anguille S, De Reu H, Berneman ZN, Smits EL, Van Tendeloo VF. Interleukin-15-cultured dendritic cells enhance anti-tumor gamma delta T cell functions through IL-15 secretion. Front Immunol. 2018;9:658.CrossRef

Title: The role of various interleukins in acute myeloid leukemia
Authors: Erin C. Kaser
Lei Zhao
Kyle P. D’mello
Ziwen Zhu
Huaping Xiao
Mark R. Wakefield
Qian Bai
Yujiang Fang
Publication date: 01-05-2021
Publisher: Springer US
Keywords: Acute Myeloid Leukemia
Leukemia
Published in: Medical Oncology / Issue 5/2021
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-021-01498-7

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The role of various interleukins in acute myeloid leukemia

Abstract

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2021

The CXCL12/CXCR7 signalling axis promotes proliferation and metastasis in cervical cancer

SNRPB is a mediator for cellular response to cisplatin in non-small-cell lung cancer

Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures

Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy

Immunotherapy and predictive immunologic profile: the tip of the iceberg

Disease spectrum of gastric cancer susceptibility genes

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page